Singapore, Sept. 5 -- In February 2025, the Ministry of Health (MoH) in Singapore announced that Shingrix will be included in the National Adult Immunisation Schedule (NAIS). With the inclusion, subsidies and MediSave usage (from mid-2026) for the vaccine will be extended to eligible Singaporeans and Permanent Residents (PRs) at public healthcare institutions and General Practitioner (GP) clinics under the Community Health Assist Scheme (CHAS).

The inclusion is effective from 1 September 2025. In addition to Shingrix, MoH and the Communicable Diseases Agency (CDA) has also included the pneumococcal vaccine, PCV20, in the NAIS from 1 September 2025.

Shingrix, a recombinant herpes zoster vaccine, is the only vaccine currently registered w...